Continuing Medical Education Information

The goal of the 2011 ASCO Annual Meeting is to foster communication among oncology-related subspecialties and the exchange of a wide range of ideas related to cancer. ASCO's objectives are to advance the education of physicians and other professionals caring for patients with cancer, to support the development of clinical cancer researchers, and to facilitate the delivery of high-quality health care to patients with cancer. The 2011 ASCO Annual Meeting is designed to serve the respective interests of the Society's multidisciplinary membership, with education focused on medical, surgical, and radiation oncology

Disclosure Information

Information for faculty, presenter and committee disclosures, as well as information on the onsite disclosure process, can be found on the Disclosure Information page.

2011 Annual Meeting General Accreditation Information

The American Society of Clinical Oncology (ASCO) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

ASCO designates this live activity for a maximum of 40 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All nonphysician attendees are welcome to submit a request for a Certificate of Participation, through the submission of the evaluation form, which may enable nonphysicians to apply their Annual Meeting participation toward re-licensure. Specific nursing and pharmacy continuing education credit is no longer offered.

Any questions related to CME may be directed to ASCO Staff at cme@asco.org or 571-483-1403.

Needs Statement

With emerging educational and scientific advances, oncology is a field where patient care standards can change very quickly. Due to the high volume of literature and best practices information available, it is important that oncologists and other cancer care providers synthesize and digest the latest evidence based information applicable to their practice/research setting.

In an effort to meet educational needs based on this rapid exchange of information, ASCO is committed to disseminating the latest scientific findings in oncology and practice-changing advances in cancer prevention, diagnosis, treatment, and survivorship.

Target Audience

The Annual Meeting is designed for U.S. and international physicians and researchers involved in multidisciplinary clinical cancer care, including but not limited to medical, surgical, and radiation oncologists; pathologists; radiologists; and other translational-oriented laboratory scientists.

The Annual Meeting can also benefit nurses, pharmacists, physician assistants, and other health care professionals involved in clinical cancer care and cancer research.

Learning Objectives

Upon participation in this activity, attendees will be able to:

• Acquire knowledge of recent and emerging data from key studies in translational and clinical cancer research
• Note how progress in cancer research has furthered knowledge of cancer biology and pathogenesis
• Incorporate knowledge gained as a result of clinical cancer research into appropriate management strategies and trial designs to improve patient outcomes
• Evaluate the role of new  imaging and pathologic techniques, as well as therapeutic approaches, as applied to the diagnosis, care and management of people with cancer
• Implement clinical and scientific strategies designed to improve the quality of cancer care 
• Effectively communicate with colleagues and with patients regarding advances in clinical oncology science
• Identify and utilize evidence-based tools for cancer risk assessment and risk reduction  
• Foster collaborations amongst domestic and international oncology specialists and scientist based on the latest scientific advances in oncology

This activity was planned in the context of the following ACGME competencies: Patient Care, Medical Knowledge, Practiced-based Learning and Improvement, Interpersonal and Communication Skills, Professionalism, and Systems-based Practice.

Unlabelled Usage Statement

The information presented is that of the contributing faculty and does not necessarily represent the views of the American Society of Clinical Oncology and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions and adverse effects.

2011 Annual Meeting Educational Supporters
ASCO and the Conquer Cancer Foundation gratefully acknowledge the following companies for supporting the education and science programs of the 2011 Annual Meeting:

American Cancer Society
American Cancer Society Award and Lecture

Amgen
Breast Cancer Track
Developmental Therapeutics Track
Gastrointestinal (Colorectal) Cancers Track
Genitourinary Cancers Track
Health Services Research Track
Pediatric Oncology Track

Boehringer Ingelheim Pharmaceuticals, Inc.
Gynecologic Cancers Track
Lung Cancer Track

Bristol-Myers Squibb
Gastrointestinal (Colorectal) Cancers Track
Gastrointestinal (Noncolorectal) Cancers Track
Head and Neck Cancers Track

Bristol-Myers Squibb and Otsuka America Pharmaceuticals, Inc.
Leukemia, Myelodysplasia and Transplantation Track

Celgene Corporation
Breast Cancer Track
Leukemia, Myelodysplasia and Transplantation Track
Lung Cancer Track
Lymphoma and Plasma Cell Disorders Track

Daiichi Sankyo, Inc.
Lung Cancer Track

Dendreon Corporation
Genitourinary Cancers Track

Eisai Inc.
Breast Cancer Track
Leukemia, Myelodysplasia and Transplantation Track
Patient and Survivor Care Track

EMD Serono Inc.
Central Nervous System Tumors Track
Lung Cancer Track

Genentech BioOncology™
Breast Cancer Track
Clinical Trials Track
Gastrointestinal (Colorectal) Cancers Track
Lung Cancer Track
Lymphoma and Plasma Cell Disorders Track
Professional Development Track
Tumor Biology Track

Kidney Cancer Association
Genitourinary Cancers Track

Lilly USA, LLC
Breast Cancer Track
Gastrointestinal (Colorectal) Cancers Track
Gynecologic Cancers Track
Head and Neck Cancers Track
Lung Cancer Track

Merck Oncology
Central Nervous System Tumors Track
Melanoma/Skin Cancers Track
Sarcoma Track

Millennium: The Takeda Oncology Company
Lymphoma and Plasma Cell Disorders Track

Novartis Oncology
Breast Cancer Track
Gastrointestinal (Noncolorectal) Cancers Track
Leukemia, Myelodysplasia and Transplantation Track
Lymphoma and Plasma Cell Disorders Track

Onyx Pharmaceuticals and Bayer Healthcare Pharmaceuticals Inc.
Gastrointestinal (Noncolorectal) Cancers Track

Pfizer Oncology
Breast Cancer Track
Gastrointestinal (Noncolorectal) Cancers Track
Genitourinary Cancers Track
Leukemia, Myelodysplasia and Transplantation Track Lung Cancer Track
Lymphoma and Plasma Cell Disorders Track
Patient and Survivor Care Track
Lung Cancer Track

sanofi-aventis U.S.
Genitourinary Cancers Track